BioLineRx Ltd. rose 9% in Tuesday’s afternoon trade after the company said it initiated a phase 2a trial that will evaluate BL-8040 in combination with Merck & Co.’s (MRK) Keytruda in patients with metastatic pancreatic cancer.
The phase 2a study will enroll up to 30 patients with metastatic pancreatic adenocarcinoma and will be conducted in the U.S., Israel and additional territories. The study will evaluate the safety, tolerability and clinical response of the combination treatment as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity.
“We believe that the combination of BL-8040 with KEYTRUDA has the potential to expand the benefit of immunotherapy to cancer types currently resistant to immuno-oncology treatments, such as pancreatic cancer, which represent a significant unmet medical need,” said BioLineRx CFO Philip Serlin.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.